Almac Clinical Technologies, a division of the Almac Group, has signed a record $12 million worth of new studies within the past several weeks, including a global mega-study involving almost 20,000 patients.
   
Almac Clinical Technologies president Jim Murphy commented, “We are seeing an increase in the number of large, global, complex trials as well as smaller adaptive clinical trials, each requiring sophisticated randomization and drug management approaches. Sponsors seem to be turning to experienced global firms, such as Almac, with strong project management expertise and technologies to make those trials successful.”